Summary statement: Retinal blood flow levels in CRVO patients after IVB.
Methods. Three patients (3 eyes) being treated with IVB (1.25 mg/0.05 ml) for secondary macular edema of CRVO were examined. LSFG analyses of the blood flow were based on examinations of the mean blur rate (MBR) at the major vessels of the optic disc. Central retinal thickness (CRT) was measured by optical coherence tomography (OCT) using Macular Cube 512 × 128 scanning protocol.
Results. After the first IVB, case 1 exhibited an increase in MBR and a decrease in CRT. Due to a subsequent MBR decrease and CRT increase four months later, an additional injection was required, which led to an increase in MBR and a decrease in CRT, similar to that observed after the first treatment. Subsequently, blood flow has continued to improve without additional IVB. Macular edema recurrence in case 2 led to three further IVBs over a six-month period. Although increases in MBR and decreases in CRT were noted, MBR values tended to decline after each IVB. In case 3, macular edema recurrence led to five additional IVBs being carried out within a one-year period. Continuous MBR increases and CRT decreases were observed in the patient after each IVB. By measuring MBR using LSFG, we may predict the prognosis of CRVO.
Conclusions. MBR increases after IVB were confirmed by LSFG in three patients. Even though CRVO pathology backgrounds can vary, LSFG may be useful in both determining the CRVO prognosis and in evaluating treatment efficacy.
Precis.
MBR increases after IVB were confirmed by LSFG in three patients. Even though CRVO pathology backgrounds can vary, LSFG may be useful in both determining the CRVO prognosis and in evaluating treatment efficacy. Vascular endothelial growth factor (VEGF) has been shown to be associated with central retinal vein occlusion (CRVO) pathology. 1,2 Therefore, anti-VEGF therapy has been proposed as a potential CRVO treatment strategy. CRVO is a disease in which the degree of ischemia varies depending upon both the individual case and the actual stage of the disease. Laser Speckle Flowgraphy (LSFG) (LSFG-Navi, Softcare, Fukuoka, Japan) is a new clinical device that can be conveniently applied to visualize and measure blood flow distribution in the ocular fundus. 3, 4 We are unaware of previous studies that have examined retinal blood flows before and after intravitreal bevacizumab injection (IVB) in CRVO cases. Therefore, this study used LSFG to investigate ocular blood flow levels in three patients after they received IVB for macular edema secondary to CRVO.
Methods. Three patients with macular edema due to CRVO were given off-label intravitreal bevacizumab (Avastin; Roche, Reinach, Switzerland). All three patients provided written informed consent prior to treatment initiation. The intravitreal dosage of bevacizumab was 1.25 mg/0.05 ml. All injections were performed in accordance with standard sterile methodology, 5 and then followed by administration of prophylactic topical antibiotics at 3 days post injection.
To evaluate retinal blood flow levels, mean blur rate (MBR) at the major vessels of the optic disc was determined by LSFG-NAVI, as has been previously described. 6 LSFG analyzer software (version 3.1.3) was used to calculate MBR in the major vessel area of the optic disc, which was averaged over the vessel area.
Central retinal thickness (CRT) was measured as mean retinal thickness in the Figure 2C ). Subsequently, the patient was given a second IVB that resulted in a decreased CRT (284 µm) and an increased MBR (38.0) ( Figure   2D ), which was similar to that observed after her first IVB treatment. Two months after the second injection, CRT was scarcely changed (289 µm) and there was only a slight decrease in MBR (30.7) ( Figure 2E ). Even though her CRT (477 µm) increased and her visual acuity (20/70) did not further change, we noted a tendency for MBR to increase, with a value of 47.5 observed at five months after the second injection ( Figure 2F ). As a result, we decided to simply continue to observe the patient without additional treatment intervention. A graph of her MBR and CRT is shown in Figure 2G . Probably, she can keep retinal blood flow high in the future, and is considered to be a good prognosis. Figure 6C ), 348 µm and 45.1 (third IVB; Figure   6D ), 343 µm and 48.6 (fourth IVB; Figure 6E ), respectively. At one month after her fifth IVB, CRT was 346 µm and MBR was 48.0 ( Figure 6F ), while at three months after her fifth IVB, CRT was 322 µm and MBR was 48.6 ( Figure 6G ).
Case
After her fifth IVB treatment, she has had no further recurrence of macular edema, and her visual acuity has remained at 20/15. A graph of her MBR and CRT is shown in Figure 6H . Probably, she can keep retinal blood flow high in the future, and is considered to be a good prognosis.
Discussion. We report three cases of macular edema secondary to non-ischemic CRVO in which the blood flow increased after IVBs. In case 1, CRT decreased and MBR increased after undergoing two IVBs. Based on the shape of the macular edema ( Figure 2F ) and the subsequent increase in blood flow, we do not believe the recurrence of macular edema was due to either recurrence or aggravation of CRVO condition. In this particular case, the improvement of macular edema and the blood flow may have been due to simply observing the natural course of the recovery after the second IVB treatment. In case 2, even though CRT decreased and MBR increased after each of the IVBs, MBR tended to fall when macular edema recurred. Since it is possible that the blood flow may continue to decrease, this might suggest that the patient may result in ischemic CRVO. As the patient's condition has yet to be stabilized, additional follow-ups will need to be done in order to find the best way to effect a cure. In case 3, even though CRT decreased and MBR increased after each of the IVB treatments, the patient was able to achieve and maintain good visual acuity, and her overall prognosis was good.
While the treatments were ultimately successful in cases 1 and 3, case 2 did not fare as well. These results suggest there may very well be a difference in the pathogenesis between case 2 and the other patients.
Although the pathogenesis of CRVO has yet to be fully understood, the major stimulus for the formation of macular edema and neovascularization in patients with CRVO appears to be hypoxia-induced production of VEGF, which is an angiogenic factor that promotes angiogenesis and increases permeability. 1 Therefore, drugs that inhibit the bioactivity of VEGF represent a new paradigm for the treatment of both retinovascular disease and macular edema.
A previous study has shown that enlargement of the foveal avascular zone and the intercapillary area causes localized retinal hypoxia. 7 Subsequently, this localized macular ischemia accompanied by CRVO may then promote an increased production of cytokines such as VEGF. It also has been reported that VEGF-induced vascular permeability is mediated, in part, by intercellular adhesion molecule 1 (ICAM-1)-mediated retinal leukostasis. 8 Leukostasis coincides with enhanced vascular permeability and capillary non-perfusion, which results in the over-expression of VEGF and a subsequent development of macular edema. In addition, Noma et al. reported finding a negative correlation between the perifoveal capillary blood-flow velocity and the retinal thickness at the central fovea in patients with branch retinal vein occlusion. 9 Inhibition of VEGF would be expected to prevent or reduce ICAM-1, thereby secondarily improving blood flow. In some patients, however, bevacizumab therapy was not found to be effective, despite the administration of multiple intravitreal injections. 10 Responses to IVB can differ from case to case, and thus, it may be that IVB is only effective in cases in which the VEGF concentration is high.
Likewise, when elements other than VEGF participate, there may be no reaction to an IVB. Furthermore, these reactions may also be restricted due to bevacizumab's limited duration of action.
Even though the background for CRVO pathology can vary, LSFG may be useful in both determining the CRVO prognosis and in evaluating the treatment efficacy.
In the present report, we only observed a few cases over a short period of time and thus, a further study that examines a larger number of cases over a longer follow-up period will need to be undertaken. Moreover, in order to definitely confirm the present results, blood flows before and after IVB in CRVO cases will also need to be determined by other types of measurement devices. At the time of the patient's first visit, CRT was 475 µm and MBR was 27.8 (A). 
